Figure 3: BMD changes after drug administration. OVX induced significant BMD decrease, which was reversed by genistein administration. The femoral BMDs in genistein-treated groups were 21.4% (L), 33.3% (M) and 30.2% (H) higher than that seen in OVX controls. The tibial BMDs in genistein-treated groups were 18.8% (L), 23.2% (M) and 22.3% (H) higher than that seen in OVX controls. Data is expressed as the mean ± SE of eight rats. *P < 0.05 vs SH, **P < 0.01 vs SH. L: low dose (4.5 mg/kg), M: mid-dose (9 mg/kg), H: high dose (18 mg/kg).